Drug Channel Updates
Timely updates on drug shortages, launches, recalls, and more.
Top shortages
Albut/Iprat AH 2.5-0.5mg/3ml 12×5 UD Increased demand.
Enulose SL 10mg/15ml 473ml Issues caused by quota restraints.
Guaifen/Cod SL 100-10/5 120ml Product on back order.
Lidocaine AP 5% 30’s Capacity constraints causing this issue.
Lorazepam Inten CN 2mg/ml 30ml Quality issues causing this problem. Some product is in stock.
Morphine Tab 15mg 100s ER In stock or in transit to the distribution centers.
Oxycod/Apap Tab 10-325mg 100s Issues caused by quota restraints.
Tizanidine Hcl Tb 4mg 1000s Increased demand causing this issue. As of 12/12, there was limited stock on hand.
Drug Launches
The latest insights on the drug market.
Recent Launches
There have been no new launches.
Upcoming Launches
Auryxia (ferric citrate) is a $249 million market and is scheduled to launch late in the first quarter of 2025. Market is still forming on this product.
Betimol (timolol) is less than a $10 million market and has been on the watch list for some time. The date continues to be moved back, and it now looks like the earliest it might launch is sometime during quarter one, 2025. Note: The 30mg has launched and this launch will be for the 10mg and 20mg strengths.
Namzaric – (donepezil/memantine), is a $100 million market and is scheduled to launch in January 2025. To date, only Amneal has announced plans to launch this generic.
Sandostatin LAR – (octreotide acetate), is a $740 million market and has been on the watch list for some time. The date continues to be moved back, and it now looks like the earliest this product might launch would be sometime during quarter one, 2025.
Xarelto 2.5mg – (rivaroxaban), is a $460 million market and is scheduled to launch in March 2025. This launch will only be for the 2.5mg strength as the other strengths (10mg, 15mg, and 20mg) are still under patent which doesn’t expire until 2027.
Day 181
Corlanor (ivabradine) is a $147 million market and will be available to others in January 2025. No additional news to report.
Victoza (liraglutide recombinant) is a $3.7 billion market and will be available to others this month. Hikma has tentative approval to enter the market and there potentially could be other vendors as well.
Recalls
The most recent recall information with return forms.
Buy-herbal.com
Company Name: Buy-herbal.com
Product Description: Nhan Sam Tuyet Lien Truy Phong Hoan dietary supplement capsules
Recall Reason: Device and drug safety – unapproved drug
Force Forever
Company Name: GNMART Inc.
Product Description: Dietary Supplement
Recall Reason: Product contains undeclared diclofenac and dexamethasone
Fouzee
Company Name: Shoppers-Plaza
Product Description: SugarLin Herbal Formula Herbal Dietary Supplement
Recall Reason: Product contains undeclared Metformin and Glyburide